Masatake Fukunami
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Masatake Fukunami has a total of 150 co-authors. Here are the top co-authors by number of shared publications:
- Tetsuya Watanabe
Department of Cardiovascular Medicine Yao Municipal Hospital Yao Japan
27 shared publications - Tsutomu Kawai
Department of Cardiology (T.F., M.K., T.Y., M.A., T.M., A.K., T. Kondo, T. Kawai, M.S., J.N., Y. Kokubu, M.F.), Osaka General Medical Center, Japan
21 shared publications - Masahiro Seo
Division of Cardiology, Osaka General Medical Center
20 shared publications - Takashi Morita
Department of Cardiology (T.F., M.K., T.Y., M.A., T.M., A.K., T. Kondo, T. Kawai, M.S., J.N., Y. Kokubu, M.F.), Osaka General Medical Center, Japan
20 shared publications - Masato Kawasaki
Division of Cardiology, Osaka General Medical Center, Osaka, Japan
18 shared publications - Yuji Nishimoto
Department of Cardiology, Toyonaka Municipal Hospital , Toyonaka 560-9565
17 shared publications
Latest Publications
- 18 November 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Imaging
Short- and Long-Term Effects of His Bundle Pacing on Myocardial Perfusion, Metabolism, and Function
BACKGROUND: Right ventricular apical pacing (RVAP) has been reported to affect myocardial metabolism and perfusion, leading to impaired left ventricular function. Right ventricular septal pacing (RVSP) and His bundle pacing (HISP) have been introduced as alternatives to RVAP. We sought to investigate the effect of RVSP and HISP on myocardial perfusion, fatty acid metabolism, and function. METHODS: We prospectively studied 104 patients (RVSP, n=44; HISP, n=17; RVAP, n=11; and sinus rhythm or right atrial pacing, n=32 as the control group) admitted for pacemaker implantation, excluding patients with coronary artery disease. Patients underwent technetium-99m methoxyisobutylisonitrile single-photon emission computed tomography and iodine-123 β-methyl iodophenyl pentadecanoic acid single-photon emission computed tomography imaging during the short-term period (3–12 months after device implantation) and in the long-term period (24 months after short-term assessment). Regional tracer activity in 17 segments on a polar map was calculated as %uptake. RESULTS: On both short- and long-term imaging, RVSP and RVAP groups showed relatively reduced sestamibi and BMIPP %uptake in septal and inferior regions compared with the control group, whereas no apparent reduction was observed in the HISP group. No significant difference in left ventricular ejection fraction was seen among RVSP, HISP, and control groups, although the RVAP group showed lower left ventricular ejection fraction. Average sestamibi and BMIPP %uptakes in 17 segments were significantly associated with left ventricular ejection fraction. CONCLUSIONS: HISP may be associated with relatively preserved myocardial perfusion, metabolism, and function compared with right ventricular pacing. REGISTRATION: URL: https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000035232 ; Unique identifier: UMIN000030858
- 18 November 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Imaging
Short- and Long-Term Effects of His Bundle Pacing on Myocardial Perfusion, Metabolism, and Function
BACKGROUND: Right ventricular apical pacing (RVAP) has been reported to affect myocardial metabolism and perfusion, leading to impaired left ventricular function. Right ventricular septal pacing (RVSP) and His bundle pacing (HISP) have been introduced as alternatives to RVAP. We sought to investigate the effect of RVSP and HISP on myocardial perfusion, fatty acid metabolism, and function. METHODS: We prospectively studied 104 patients (RVSP, n=44; HISP, n=17; RVAP, n=11; and sinus rhythm or right atrial pacing, n=32 as the control group) admitted for pacemaker implantation, excluding patients with coronary artery disease. Patients underwent technetium-99m methoxyisobutylisonitrile single-photon emission computed tomography and iodine-123 β-methyl iodophenyl pentadecanoic acid single-photon emission computed tomography imaging during the short-term period (3–12 months after device implantation) and in the long-term period (24 months after short-term assessment). Regional tracer activity in 17 segments on a polar map was calculated as %uptake. RESULTS: On both short- and long-term imaging, RVSP and RVAP groups showed relatively reduced sestamibi and BMIPP %uptake in septal and inferior regions compared with the control group, whereas no apparent reduction was observed in the HISP group. No significant difference in left ventricular ejection fraction was seen among RVSP, HISP, and control groups, although the RVAP group showed lower left ventricular ejection fraction. Average sestamibi and BMIPP %uptakes in 17 segments were significantly associated with left ventricular ejection fraction. CONCLUSIONS: HISP may be associated with relatively preserved myocardial perfusion, metabolism, and function compared with right ventricular pacing. REGISTRATION: URL: https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000035232 ; Unique identifier: UMIN000030858
- Open Access
- 16 November 2026
- Published by Oxford University Press (OUP) in EP Europace
Predictors and Long-term Prognosis of Silent Cerebral Embolism After Catheter Ablation of Atrial Fibrillation
- 16 November 2026
- Published by Oxford University Press (OUP) in EP Europace
Open AccessPredictors and Long-term Prognosis of Silent Cerebral Embolism After Catheter Ablation of Atrial Fibrillation
- Open Access
- 4 February 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (3) , e037652
Effectiveness of an Impella Versus Intra‐Aortic Balloon Pump in Patients Who Received Extracorporeal Membrane Oxygenation
Background: It is unclear whether an intra‐aortic balloon pump (IABP) or percutaneous ventricular assist device (Impella) in combination with extracorporeal membrane oxygenation (ECMO) is better. Methods: Using the Japanese Diagnosis Procedure Combination database from September 2016 to March 2022, we identified inpatients who received an Impella or IABP in combination with ECMO (ECPella or ECMO+IABP group, respectively). The primary outcome was in‐hospital mortality, and the secondary outcomes included the length of hospital stay, length of ECMO, total hospitalization cost, complications, and durable mechanical circulatory support implantations. Propensity score matching was performed to compare the outcomes between the groups. Results: Of 14 319 eligible patients, 590 (4.1%) received ECPella and 13 729 (96%) received ECMO+IABP. The mean age of patients was 65 years, 77% were men, and 57% had acute coronary syndrome. After propensity score matching, the patient characteristics were well balanced between the groups. The 14‐day mortality rate was lower in the ECPella group than in the ECMO+IABP group (28.0% versus 36.8%; risk difference, −8.2% [95% CI, −13.8 to −2.7]), whereas there was no significant difference in in‐hospital mortality between the groups (58.3% versus 56.6%; risk difference, 2.4% [95% CI, −3.5 to 8.2]). The ECPella group had a higher total hospitalization cost, increased renal replacement therapy during hospitalization, and more durable mechanical circulatory support implantations than the ECMO+IABP group. Conclusions: This nationwide inpatient database study showed no significant difference in in‐hospital mortality between the groups, but ECPella was associated with a higher total hospitalization cost, increased renal replacement therapy during hospitalization, and more durable mechanical circulatory support implantations than ECMO+IABP.
- 4 February 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (3) , e037652
Open AccessEffectiveness of an Impella Versus Intra‐Aortic Balloon Pump in Patients Who Received Extracorporeal Membrane Oxygenation
Background: It is unclear whether an intra‐aortic balloon pump (IABP) or percutaneous ventricular assist device (Impella) in combination with extracorporeal membrane oxygenation (ECMO) is better. Methods: Using the Japanese Diagnosis Procedure Combination database from September 2016 to March 2022, we identified inpatients who received an Impella or IABP in combination with ECMO (ECPella or ECMO+IABP group, respectively). The primary outcome was in‐hospital mortality, and the secondary outcomes included the length of hospital stay, length of ECMO, total hospitalization cost, complications, and durable mechanical circulatory support implantations. Propensity score matching was performed to compare the outcomes between the groups. Results: Of 14 319 eligible patients, 590 (4.1%) received ECPella and 13 729 (96%) received ECMO+IABP. The mean age of patients was 65 years, 77% were men, and 57% had acute coronary syndrome. After propensity score matching, the patient characteristics were well balanced between the groups. The 14‐day mortality rate was lower in the ECPella group than in the ECMO+IABP group (28.0% versus 36.8%; risk difference, −8.2% [95% CI, −13.8 to −2.7]), whereas there was no significant difference in in‐hospital mortality between the groups (58.3% versus 56.6%; risk difference, 2.4% [95% CI, −3.5 to 8.2]). The ECPella group had a higher total hospitalization cost, increased renal replacement therapy during hospitalization, and more durable mechanical circulatory support implantations than the ECMO+IABP group. Conclusions: This nationwide inpatient database study showed no significant difference in in‐hospital mortality between the groups, but ECPella was associated with a higher total hospitalization cost, increased renal replacement therapy during hospitalization, and more durable mechanical circulatory support implantations than ECMO+IABP.
- Open Access
- 28 June 2024
- Published by Wiley in Journal of Arrhythmia
- Vol. 40 (4) , 1029-1034
A case of biatrial tachycardia involving the intercaval bundle with assumed dual loop reentry
Epicardial connections provided the anatomical substrate for the biatrial reentry circuit. The connections between the right atrium and right pulmonary vein were called "intercaval bundle," and there are few reports of atrial flutter related to this bundle. We present a case of a biatrial tachycardia, involving the intercaval bundle.image
- 28 June 2024
- Published by Wiley in Journal of Arrhythmia
- Vol. 40 (4) , 1029-1034
Open AccessA case of biatrial tachycardia involving the intercaval bundle with assumed dual loop reentry
Epicardial connections provided the anatomical substrate for the biatrial reentry circuit. The connections between the right atrium and right pulmonary vein were called "intercaval bundle," and there are few reports of atrial flutter related to this bundle. We present a case of a biatrial tachycardia, involving the intercaval bundle.image
- 25 April 2024
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 127, 74-83
Direct oral anticoagulant-associated bleeding complications in patients with gastrointestinal cancer and venous thromboembolism
- 25 April 2024
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 127, 74-83
Direct oral anticoagulant-associated bleeding complications in patients with gastrointestinal cancer and venous thromboembolism
- Open Access
Effectiveness of an Impella versus intra-aortic balloon pump in patients who received extracorporeal membrane oxygenation
Background: Previous studies have suggested that left ventricular (LV) unloading with an intra-aortic balloon pump (IABP) or percutaneous ventricular assist device (Impella) in combination with extracorporeal membrane oxygenation (ECMO) is associated with lower mortality; however, it is unclear which is better. This study aimed to evaluate the effectiveness of LV unloading with an Impella versus IABP on in-hospital mortality and other clinical outcomes. Methods: Using the Japanese Diagnosis Procedure Combination database from September 28, 2016, to March 31, 2022, we identified inpatients who received an Impella or IABP in combination with ECMO (ECPella or ECMO+IABP group, respectively). The primary outcome was in-hospital mortality and the secondary outcomes were the length of hospital stay, length of ECMO, total hospitalization cost, and complications. Propensity score matching was performed to compare the outcomes between the groups. Results: Of 14,525 eligible patients, 603 (4.2%) received ECPella and 13,922 (96%) received ECMO+IABP. After propensity score matching, there was no significant difference in in-hospital mortality between the two groups (58.9% versus 56.6%; risk difference, 2.3%; 95% confidence interval, −3.9% to 8.5%). The ECPella group had a longer hospital stay, higher total hospitalization cost, and more frequent major bleeding, vascular complications, and renal replacement therapy during hospitalization than the ECMO+IABP group. Conclusions: This nationwide inpatient database study showed that ECPella was not associated with a survival benefit but was associated with a longer hospital stay, higher total hospitalization cost, and more complications than ECMO+IABP.
Open AccessEffectiveness of an Impella versus intra-aortic balloon pump in patients who received extracorporeal membrane oxygenation
Background: Previous studies have suggested that left ventricular (LV) unloading with an intra-aortic balloon pump (IABP) or percutaneous ventricular assist device (Impella) in combination with extracorporeal membrane oxygenation (ECMO) is associated with lower mortality; however, it is unclear which is better. This study aimed to evaluate the effectiveness of LV unloading with an Impella versus IABP on in-hospital mortality and other clinical outcomes. Methods: Using the Japanese Diagnosis Procedure Combination database from September 28, 2016, to March 31, 2022, we identified inpatients who received an Impella or IABP in combination with ECMO (ECPella or ECMO+IABP group, respectively). The primary outcome was in-hospital mortality and the secondary outcomes were the length of hospital stay, length of ECMO, total hospitalization cost, and complications. Propensity score matching was performed to compare the outcomes between the groups. Results: Of 14,525 eligible patients, 603 (4.2%) received ECPella and 13,922 (96%) received ECMO+IABP. After propensity score matching, there was no significant difference in in-hospital mortality between the two groups (58.9% versus 56.6%; risk difference, 2.3%; 95% confidence interval, −3.9% to 8.5%). The ECPella group had a longer hospital stay, higher total hospitalization cost, and more frequent major bleeding, vascular complications, and renal replacement therapy during hospitalization than the ECMO+IABP group. Conclusions: This nationwide inpatient database study showed that ECPella was not associated with a survival benefit but was associated with a longer hospital stay, higher total hospitalization cost, and more complications than ECMO+IABP.
- Open Access
Net Clinical Benefit of Edoxaban for 12 versus 3 Months in Cancer-associated Isolated Distal Deep Vein Thrombosis: ONCO DVT study
Background: The ONCO DVT (Edoxaban for 12 Months Versus 3 Months in Patients With Cancer With Isolated Distal Deep Vein Thrombosis) study has revealed the superiority of a 12-month versus 3-month edoxaban treatment in terms of fewer thrombotic events for cancer-associated isolated distal deep vein thrombosis; however, concern for increased bleeding with longer anticoagulation remains. Methods: In this post-hoc analysis of the ONCO DVT study, we compared 12-month and 3-month edoxaban treatments in terms of the net adverse clinical events (NACE) as a composite endpoint of the primary endpoint (symptomatic recurrent VTE and VTE-related death at 12 months) and major secondary endpoint (major bleeding at 12-months) of the ONCO DVT study. The net clinical benefit of a 12-month over 3-month treatment was defined as the sum of the differences in the incidence of thrombotic and bleeding events between the 3-month and 12-month treatments. The weight of bleeding events was set at 1.0, and we assessed the changes in the net clinical benefit with weights of bleeding events set at 0.5 and 2.0. Results: With a weight of bleeding events of 1.0, NACE occurred in 30 of 296 patients (10.1%) in the 12-month edoxaban group and in 42 of 305 patients (13.8%) in the 3-month edoxaban group. The net clinical benefit was 3.6% (95% CI, -1.5% to 8.8%). There was a significant treatment-by-subgroup interaction between the thrombocytopenia or cancer metastasis subgroup factors and the effect of the 12-month relative to the 3-month treatment for NACE. As the weights of bleeding events changed from 0.5 to 2.0, the net clinical benefit in the 12-month edoxaban group as compared to the 3-month edoxaban group became attenuated from 4.8% (95% CI, 0.5% to 9.0%) to 0.7% (95% CI, -5.7% to 7.1%). Conclusions: The net clinical benefit of the 12-month over 3-month edoxaban treatment was not significant; however, the 12-month treatment had a numerically lower incidence of NACE than the 3-month treatment. Clinical Trial Registration: ClinicalTrials.gov, NCT03895502 . Clinical Perspective: What is new?: The net clinical benefit of the 12-month over 3-month edoxaban treatment was not significant in terms of the net clinical adverse events (NACE) combined with symptomatic recurrent venous thromboembolism (VTE), VTE-related death, or major bleeding with a weight of bleeding events of 1.0, however, the 12-month group had a numerically lower incidence of the NACE than the 3-month group. The net clinical benefit of the 12-month over 3-month edoxaban treatment became attenuated as the weights of the bleeding events increased. What are the clinical implications?: The present study revealed that the 12-month edoxaban treatment compared with the 3-month edoxaban treatment was basically favorable in terms of NACE; however, the net clinical benefit of the 12-month edoxaban treatment became attenuated as the weights of the bleeding events increased. Further studies should be required to evaluate the case fatality rate of each event and its impact on cancer treatment.
Open AccessNet Clinical Benefit of Edoxaban for 12 versus 3 Months in Cancer-associated Isolated Distal Deep Vein Thrombosis: ONCO DVT study
Background: The ONCO DVT (Edoxaban for 12 Months Versus 3 Months in Patients With Cancer With Isolated Distal Deep Vein Thrombosis) study has revealed the superiority of a 12-month versus 3-month edoxaban treatment in terms of fewer thrombotic events for cancer-associated isolated distal deep vein thrombosis; however, concern for increased bleeding with longer anticoagulation remains. Methods: In this post-hoc analysis of the ONCO DVT study, we compared 12-month and 3-month edoxaban treatments in terms of the net adverse clinical events (NACE) as a composite endpoint of the primary endpoint (symptomatic recurrent VTE and VTE-related death at 12 months) and major secondary endpoint (major bleeding at 12-months) of the ONCO DVT study. The net clinical benefit of a 12-month over 3-month treatment was defined as the sum of the differences in the incidence of thrombotic and bleeding events between the 3-month and 12-month treatments. The weight of bleeding events was set at 1.0, and we assessed the changes in the net clinical benefit with weights of bleeding events set at 0.5 and 2.0. Results: With a weight of bleeding events of 1.0, NACE occurred in 30 of 296 patients (10.1%) in the 12-month edoxaban group and in 42 of 305 patients (13.8%) in the 3-month edoxaban group. The net clinical benefit was 3.6% (95% CI, -1.5% to 8.8%). There was a significant treatment-by-subgroup interaction between the thrombocytopenia or cancer metastasis subgroup factors and the effect of the 12-month relative to the 3-month treatment for NACE. As the weights of bleeding events changed from 0.5 to 2.0, the net clinical benefit in the 12-month edoxaban group as compared to the 3-month edoxaban group became attenuated from 4.8% (95% CI, 0.5% to 9.0%) to 0.7% (95% CI, -5.7% to 7.1%). Conclusions: The net clinical benefit of the 12-month over 3-month edoxaban treatment was not significant; however, the 12-month treatment had a numerically lower incidence of NACE than the 3-month treatment. Clinical Trial Registration: ClinicalTrials.gov, NCT03895502 . Clinical Perspective: What is new?: The net clinical benefit of the 12-month over 3-month edoxaban treatment was not significant in terms of the net clinical adverse events (NACE) combined with symptomatic recurrent venous thromboembolism (VTE), VTE-related death, or major bleeding with a weight of bleeding events of 1.0, however, the 12-month group had a numerically lower incidence of the NACE than the 3-month group. The net clinical benefit of the 12-month over 3-month edoxaban treatment became attenuated as the weights of the bleeding events increased. What are the clinical implications?: The present study revealed that the 12-month edoxaban treatment compared with the 3-month edoxaban treatment was basically favorable in terms of NACE; however, the net clinical benefit of the 12-month edoxaban treatment became attenuated as the weights of the bleeding events increased. Further studies should be required to evaluate the case fatality rate of each event and its impact on cancer treatment.
- Open Access
- 9 November 2023
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 44 (Supplement)
Remote ischemic peri-conditioning suppressed the activation of cardiac sympathetic nervous system in patients with acute myocardial infarction: a randomized controlled trial
Background: The activation of cardiac sympathetic nervous system is associated with poor prognosis in patients with acute myocardial infarction (AMI). Remote ischemic peri-conditioning (RIPC) is reported to improve clinical outcome in patients with AMI. However, there is not fully clarified whether RIPC could have an effect on cardiac sympathetic activity. Purpose: The purpose of this study is to investigate the effect of RIPC on cardiac sympathetic activity in patients with AMI. Methods: We randomly assigned 157 patients with suspected AMI undergoing emergent percutaneous coronary intervention to receive transient limb ischemia (by inflating a cuff at 200 mmHg for 4×5 minutes: RIPC group, n=77) or no procedure (control group, n=80) upon arrival to the cardiac catheterization laboratory. After excluding inappropriate patients such as those who were diagnosed with other than AMI, we analyzed 122 patients (62 patients in RIPC and 60 in control group). The primary endpoint was cardiac sympathetic activity assessed by the cardiac MIBG imaging washout rate (WR) at discharge and 1 year after discharge. WR and late heart-to-mediastinum ratio (HMR) in cardiac MIBG was calculated from the chest anterior view images obtained at 20 and 200 min after isotope injection. Results: Patients in RIPC and control group had similar demographic and clinical characteristics at baseline. There was no significant difference in WR between two groups at discharge. Although WR was significantly decreased 1 year after the discharge in both groups, patients in RIPC group showed significantly lower WR than those in control group (22.0 [15.1-30.6]% and 26.5 [18.4-34.4]%, p=0.0269) 1 year after the discharge. Late HMR significantly decreased during 1-year follow-up in patients only in RIPC group (p=0.0133) and patients in RIPC group tended to show higher late HMR compared to those in control group (2.01 [1.79-2.25] and 1.92 [1.72-2.11], p=0.0581) 1 year after the discharge. Conclusion(s): Remote ischemic peri-conditioning could suppress the augmented cardiac sympathetic activity in patients with acute myocardial infarction during 1-year follow-up.
- 9 November 2023
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 44 (Supplement)
Open AccessRemote ischemic peri-conditioning suppressed the activation of cardiac sympathetic nervous system in patients with acute myocardial infarction: a randomized controlled trial
Background: The activation of cardiac sympathetic nervous system is associated with poor prognosis in patients with acute myocardial infarction (AMI). Remote ischemic peri-conditioning (RIPC) is reported to improve clinical outcome in patients with AMI. However, there is not fully clarified whether RIPC could have an effect on cardiac sympathetic activity. Purpose: The purpose of this study is to investigate the effect of RIPC on cardiac sympathetic activity in patients with AMI. Methods: We randomly assigned 157 patients with suspected AMI undergoing emergent percutaneous coronary intervention to receive transient limb ischemia (by inflating a cuff at 200 mmHg for 4×5 minutes: RIPC group, n=77) or no procedure (control group, n=80) upon arrival to the cardiac catheterization laboratory. After excluding inappropriate patients such as those who were diagnosed with other than AMI, we analyzed 122 patients (62 patients in RIPC and 60 in control group). The primary endpoint was cardiac sympathetic activity assessed by the cardiac MIBG imaging washout rate (WR) at discharge and 1 year after discharge. WR and late heart-to-mediastinum ratio (HMR) in cardiac MIBG was calculated from the chest anterior view images obtained at 20 and 200 min after isotope injection. Results: Patients in RIPC and control group had similar demographic and clinical characteristics at baseline. There was no significant difference in WR between two groups at discharge. Although WR was significantly decreased 1 year after the discharge in both groups, patients in RIPC group showed significantly lower WR than those in control group (22.0 [15.1-30.6]% and 26.5 [18.4-34.4]%, p=0.0269) 1 year after the discharge. Late HMR significantly decreased during 1-year follow-up in patients only in RIPC group (p=0.0133) and patients in RIPC group tended to show higher late HMR compared to those in control group (2.01 [1.79-2.25] and 1.92 [1.72-2.11], p=0.0581) 1 year after the discharge. Conclusion(s): Remote ischemic peri-conditioning could suppress the augmented cardiac sympathetic activity in patients with acute myocardial infarction during 1-year follow-up.
- Open Access
- 9 November 2023
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 44 (Supplement)
Incidence and predictors of asymptomatic cerebral infarction following radiofrequency catheter ablation for atrial fibrillation
Backgrounds: Left atrial catheter ablation has been established as an important treatment option for atrial fibrillation (AF), but it carries the risk of periprocedural thromboembolism. Periprocedural major stroke is rare, but silent stroke does not appear to be rare. Accurate risk stratification for stroke and appropriate anticoagulation management are essential. Purpose: We aimed to investigate the incidence and predictors of silent cerebral infarction (CI) associated with AF catheter ablation, detected by diffusion-weighted magnetic resonance imaging (DW-MRI). Methods and Results: We performed a retrospective analysis of 618 consecutive patients (age 72±10 years, persistent atrial fibrillation (PEF) 45%, CHA2DS2-VASc score 2.6±1.4) with persistent or paroxysmal AF that underwent pulmonary vein (PV) or additional ablation and post-procedural cerebral MRI 1 day after ablation. During the ablation procedure, activated clotting time (ACT) was checked every 20 minutes, and additional heparin boluses were administered as needed to maintain ACT >320 seconds. Patients were analyzed for possible demographical, medical, echocardiographic, and procedural predictors of infarction events. Post-procedure DW-MRI detected new infarction lesions in 83 patients (13.4%:CI-group). There were no differences between the CI and non-CI groups with respect to age, type of anticoagulant and complex fractionated atrial electrogram ablation. Body weight, brain natriuretic peptide and left atrial diameter were significantly higher in the CI group. Left ventricular ejection fraction (LVEF) was significantly lower in the CI than non-CI group (58.6±12.6 vs. 64.2±11.8, P<0.001). PEF was more frequent in patients with CI than non-CI group (63.9 vs. 42.1%, P<0.001). In a multivariate regression model revealed only EF was a significant predictor for the occurrence of new asymptomatic lesions on post-procedural DW-MRI (OR 0.949, 95% CI 0.92-0.98, P=0.001). Conclusions: This study shows a high incidence of silent micro-embolic events after AF ablation. Lower LVEF were potential predictors of this complication.
- 9 November 2023
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 44 (Supplement)
Open AccessIncidence and predictors of asymptomatic cerebral infarction following radiofrequency catheter ablation for atrial fibrillation
Backgrounds: Left atrial catheter ablation has been established as an important treatment option for atrial fibrillation (AF), but it carries the risk of periprocedural thromboembolism. Periprocedural major stroke is rare, but silent stroke does not appear to be rare. Accurate risk stratification for stroke and appropriate anticoagulation management are essential. Purpose: We aimed to investigate the incidence and predictors of silent cerebral infarction (CI) associated with AF catheter ablation, detected by diffusion-weighted magnetic resonance imaging (DW-MRI). Methods and Results: We performed a retrospective analysis of 618 consecutive patients (age 72±10 years, persistent atrial fibrillation (PEF) 45%, CHA2DS2-VASc score 2.6±1.4) with persistent or paroxysmal AF that underwent pulmonary vein (PV) or additional ablation and post-procedural cerebral MRI 1 day after ablation. During the ablation procedure, activated clotting time (ACT) was checked every 20 minutes, and additional heparin boluses were administered as needed to maintain ACT >320 seconds. Patients were analyzed for possible demographical, medical, echocardiographic, and procedural predictors of infarction events. Post-procedure DW-MRI detected new infarction lesions in 83 patients (13.4%:CI-group). There were no differences between the CI and non-CI groups with respect to age, type of anticoagulant and complex fractionated atrial electrogram ablation. Body weight, brain natriuretic peptide and left atrial diameter were significantly higher in the CI group. Left ventricular ejection fraction (LVEF) was significantly lower in the CI than non-CI group (58.6±12.6 vs. 64.2±11.8, P<0.001). PEF was more frequent in patients with CI than non-CI group (63.9 vs. 42.1%, P<0.001). In a multivariate regression model revealed only EF was a significant predictor for the occurrence of new asymptomatic lesions on post-procedural DW-MRI (OR 0.949, 95% CI 0.92-0.98, P=0.001). Conclusions: This study shows a high incidence of silent micro-embolic events after AF ablation. Lower LVEF were potential predictors of this complication.
- Open Access
- 9 November 2023
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 44 (Supplement)
Serum cholinesterase level provides the additional long-time prognostic information over AHEAD risk score in patients with acute decompensated heart failure with preserved ejection fraction
Background and purpose: In patients with heart failure with preserved ejection fraction (HFpEF), comorbidities strongly influence the prognosis. AHEAD (A: atrial fibrillation; H: hemoglobin; E: elderly; A: abnormal renal parameters; D: diabetes mellitus) score is a simple risk model based on several comorbidities. Its prognostic role has been reported in patients with HFpEF. Although malnutrition is one of the most important comorbidities, it is not included in AHEAD score. We previously reported the prognostic value of cholinesterase (CHE), which is a simple nutritional biomarker in daily practice, in patients with HFpEF. Here, we aimed to investigate whether serum CHE level provides the additional prognostic information over AHEAD risk score in patients with HFpEF. Methods: We studied 888 patients admitted for acute decompensated heart failure (ADHF) in our multicenter-prospective HFpEF cohort study (PURSUIT-HFpEF registry). Laboratory data including CHE was obtained at discharge. We evaluated AHEAD risk score (range 0-5, atrial fibrillation, hemoglobin 70years, creatinine >130μmol/L, and diabetes mellitus).The endpoint of this study was set as the composite of worsening heart failure readmission and all-cause mortality. Results: During a follow up period of 1.6±1.3 years, 428 patients experienced primary composite endpoint. On multivariate Cox analysis, CHE (p<0.001) and AHEAD risk score (p = 0.003) were independently and significantly associated with primary composite endpoint. Kaplan-Meier analysis that patients with higher AHEAD risk score (defined as 4-5 point) and those with intermediate AHEAD score (defined as 2-3 point) had significantly greater risk of primary composite endpoint than those with low AHEAD score (defined as 0-1 point) (67% vs 54% vs 37%, log-rank p<0.001). Kaplan-Meier analysis in the subgroup with low AHEAD risk score revealed that primary composite event was significantly more frequently observed in patients with low CHE (<207 IU/L determined by the median of the whole cohort) (56% vs 28% p = 0.009). Moreover, in the subgroup with intermediate AHEAD risk score, the incidence of primary composite event was also significantly higher in patients with low CHE (56% vs 37% p<0.001). Finally, in the subgroup with high AHEAD risk score, the incidence of primary outcome was also significantly higher in patients with low CHE (69% vs 48% p<0.001). Receiver operating curve analysis showed that the addition of CHE significantly improved the risk prediction of AHEAD score (AUC: 0.641 vs 0.573, p<0.001). Conclusion: Malnutrition, as evaluated by serum cholinesterase level, provided the additional long-time prognostic information beyond AHEAD risk score in patients with ADHF-HFpEF.
- 9 November 2023
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 44 (Supplement)
Open AccessSerum cholinesterase level provides the additional long-time prognostic information over AHEAD risk score in patients with acute decompensated heart failure with preserved ejection fraction
Background and purpose: In patients with heart failure with preserved ejection fraction (HFpEF), comorbidities strongly influence the prognosis. AHEAD (A: atrial fibrillation; H: hemoglobin; E: elderly; A: abnormal renal parameters; D: diabetes mellitus) score is a simple risk model based on several comorbidities. Its prognostic role has been reported in patients with HFpEF. Although malnutrition is one of the most important comorbidities, it is not included in AHEAD score. We previously reported the prognostic value of cholinesterase (CHE), which is a simple nutritional biomarker in daily practice, in patients with HFpEF. Here, we aimed to investigate whether serum CHE level provides the additional prognostic information over AHEAD risk score in patients with HFpEF. Methods: We studied 888 patients admitted for acute decompensated heart failure (ADHF) in our multicenter-prospective HFpEF cohort study (PURSUIT-HFpEF registry). Laboratory data including CHE was obtained at discharge. We evaluated AHEAD risk score (range 0-5, atrial fibrillation, hemoglobin 70years, creatinine >130μmol/L, and diabetes mellitus).The endpoint of this study was set as the composite of worsening heart failure readmission and all-cause mortality. Results: During a follow up period of 1.6±1.3 years, 428 patients experienced primary composite endpoint. On multivariate Cox analysis, CHE (p<0.001) and AHEAD risk score (p = 0.003) were independently and significantly associated with primary composite endpoint. Kaplan-Meier analysis that patients with higher AHEAD risk score (defined as 4-5 point) and those with intermediate AHEAD score (defined as 2-3 point) had significantly greater risk of primary composite endpoint than those with low AHEAD score (defined as 0-1 point) (67% vs 54% vs 37%, log-rank p<0.001). Kaplan-Meier analysis in the subgroup with low AHEAD risk score revealed that primary composite event was significantly more frequently observed in patients with low CHE (<207 IU/L determined by the median of the whole cohort) (56% vs 28% p = 0.009). Moreover, in the subgroup with intermediate AHEAD risk score, the incidence of primary composite event was also significantly higher in patients with low CHE (56% vs 37% p<0.001). Finally, in the subgroup with high AHEAD risk score, the incidence of primary outcome was also significantly higher in patients with low CHE (69% vs 48% p<0.001). Receiver operating curve analysis showed that the addition of CHE significantly improved the risk prediction of AHEAD score (AUC: 0.641 vs 0.573, p<0.001). Conclusion: Malnutrition, as evaluated by serum cholinesterase level, provided the additional long-time prognostic information beyond AHEAD risk score in patients with ADHF-HFpEF.